Do Rickettsia typhi IgM and Ehrlichia chaffeensis IgG indicate active dual infection?

In a 74-year-old woman, Rickettsia typhi IgM and Ehrlichia chaffeensis IgG reactivity should be interpreted as evidence of antibody binding—not as proof of active dual infection. The central conclusion is well supported: serology alone cannot establish that both organisms are currently active.

Interpretation of the antibody findings

• R. typhi OmpB IgM and E. chaffeensis IgG plausibly indicate immune recognition extending beyond Borrelia, but this inference is only moderate-confidence and is not definitively organism-specific.
• E. chaffeensis IgG is consistent with prior exposure/recognition. Antibodies may persist for months, and serology can cross-react with Anaplasma antibodies or fail to distinguish among Ehrlichia species.
• R. typhi IgM is especially difficult to interpret: rickettsial IgM may persist (estimated median half-life 126 days in murine typhus patients), cross-react, or be falsely positive. CDC considers R. typhi IgM less specific and unreliable for diagnosis.

Establishing recent or active infection

• A single E. chaffeensis IgG titer—even ≥1:128—is presumptive rather than confirmatory. A ≥4-fold rise between acute and convalescent IgG samples is confirmatory evidence of recent ehrlichiosis.
• For flea-borne typhus, the preferred serologic confirmation is likewise a ≥4-fold rise in paired R. typhi IgG titers.
• Early whole-blood PCR can provide direct supportive evidence for ehrlichiosis or R. typhi, particularly before doxycycline; however, a negative PCR does not exclude infection.

Bottom line

• The results can plausibly reflect immune recognition beyond Borrelia, but cross-reactivity, persistence, and false-positive IgM limit organism-specific interpretation. They do not demonstrate concurrent active R. typhi and E. chaffeensis infection without appropriately timed paired serology and/or direct testing.